Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 9DX adjuvant nivolumab versus placebo in hepatocellular carcinoma
2017-002755-29Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Nivolumab with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Dec 2017; status: active.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-002755-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002755-29.